Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Morales Kastresana, Aizea ^a   Labiano, Sara ^a   Gütgemann, Ines ^b   Melero, Ignacio ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

B7 H1 (PD L1); CD137 (4 1BB); Immunotherapy; OX40 (CD134); T lymphocytes

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; MYC PROTEIN; OVALBUMIN; PROGRAMMED DEATH 1 LIGAND 1;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; NATURAL KILLER T CELL; NONHUMAN; TUMOR IMMUNITY;

EID: 84899048617     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27812     Document Type: Article

References (10)

1. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997-1008; PMID:23460531; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214.
2. Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MW, Yoshizawa H, Yagita H, Gejyo F, Okumura K, Smyth MJ. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol 2010; 184:5493-501; PMID:20400706; http://dx.doi.org/10.4049/jimmunol.0903033.
3. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, Gejyo F, Okumura K, Yagita H, Smyth MJ. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006; 12:693-8; PMID:16680149; http://dx.doi. org/10.1038/nm1405.
4. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482:405-9; PMID:22318517; http://dx.doi. org/10.1038/nature10803.
5. Ney JT, Schmidt T, Kurts C, Zhou Q, Eckert D, Felsher DW, Schorle H, Knolle P, Tüting T, Barchet W, et al. Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology 2009; 49:471-81; PMID:19105207; http://dx.doi.org/10.1002/hep.22652.
6. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106; PMID:17251916; http://dx.doi.org/10.1038/nrc2051.
7. Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 2013; 19:6151-62; PMID:24030703; http://dx.doi.org/10.1158/1078-0432.CCR-13-1189.
8. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer-response. Clin Cancer Res 2013; 19:5542; PMID:24048329; http://dx.doi.org/10.1158/1078-0432.CCR-13-2234.
9. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013; 19:1044-53; PMID:23460535; http://dx.doi.org/10.1158/1078-0432.CCR-12-2065.
10. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013; 59:81-8; PMID:23466307; http://dx.doi.org/10.1016/j.jhep.2013.02.022.